M2 Europharma articles from January 2002

M2 Europharma archives from January 2002

BioPhausia signs distribution agreement in the Netherlands.(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish pharmaceutical company BioPhausia AB has signed a distribution agreement with the Dutch company DeVriMed. Under the agreement DeVriMed will offer BioPhausia's RescueFlow...

Orion Pharma's new R&D facility close to completion.
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Orion Pharma, a unit of the Finnish pharmaceuticals group Orion Corp, reports that the building it is currently constructing in Turku, Finland to expand the company's research and...

AstraZeneca posts net profit of USD2.97bn for 2001.(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish pharmaceutical company AstraZeneca Plc reports that its total sales were worth USD16,480m in 2001, compared to USD15,804m in the previous year. Sales increased in...

deCODE and Roche sign drug discovery and development agreement.(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Icelandic biotechnology company deCODE genetics Inc and the Swiss-based healthcare group Roche have signed a three-year agreement that will focus on turning the achievements of their...

Biolight takes first step into Asian markets.(Biolight International AB)(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Biolight International AB has signed a distribution agreement with Taiwan's C&N Med-Dent CO Ltd and a letter of intent with Japan's Denics International...

Lundbeck gets interim approval in USA for new depression drug.(H. Lundbeck A/S)(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish pharmaceutical company H. Lundbeck A/S has received interim approval from the US Food and Drug Administration for its Cipralex drug as a treatment for depression and panic...

US health authorities approve Eligard 7.5mg for prostate cancer treatment.(from Sanofi-Synthelabo, Atrix Laboratories)(Brief Article)
January 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The French pharmaceutical group Sanofi-Synthelabo and the US-based drug development company Atrix Laboratories Inc have received approval from the US Food and Drug Administration for the...

>TI Vitrolife gets European clearance for surgery product.(Brief Article)
January 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Vitrolife AB has received marketing approval from the European Community for its new coronary by-pass surgery kit. The Vitrolife Vascular...

>TI Altana to go public in USA.(Brief Article)
January 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German pharmaceutical and specialty chemicals company Altana AG will list its shares as American depositary receipts on the New York Stock Exchange on 22 May. The listing is part...

>TI US sales of AstraZeneca's ulcer drug slow.(Brief Article)
January 28, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Nexium, the new stomach ulcer drug of the Anglo-Swedish pharmaceutical company AstraZeneca Plc, is reportedly not selling as well as expected in the US markets. The drug had a market...

>TI IDL Biotech adds research products to product portfolio.(Brief Article)
January 28, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company IDL Biotech AB has signed a collaboration agreement with a team of scientists at the University of Hong Kong. The agreement gives IDL Biotech a...

>TI AstraZeneca submits application for new cancer drug to Japanese authorities.(Brief Article)
January 28, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has submitted a marketing application for its Iressa cancer drug to the Japanese health authorities. The application is for approval of...

>TI MediTeam Dental to merge with Biolin Medical.(Brief Article)
January 28, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish dental care company MediTeam Dental AB and the Stockholm-based bio/medical technology firm Biolin Medical AB have unveiled plans to merge to form a new company that focuses on...

>TI Tripep reports SEK68.6m loss for 2001.(Brief Article)
January 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Tripep AB has posted an operating loss of SEK68.6m for 2001, compared to a loss of SEK56.5m in the previous year. In its statement released today (25...

>TI US health authorities approve Swedish Orphan's drug.(Brief Article)
January 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Stockholm-based pharmaceutical company Swedish Orphan International AB has received marketing approval from the US Food and Drug Agency for Orfadin Capsules (nitisinone), its drug...

Biolight International gets US approval for physiotherapeutic care device.(Brief Article)
January 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US Food and Drug Administration has given the Swedish biotechnology company Biolight International AB approval to market its Biolight physiotherapeutic care device in the US as a...

Pain Therapeutics gets approval to launch clinical study in Britain.(Brief Article)
January 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US pharmaceutical company Pain Therapeutics Inc has received permission from the UK Medicines Control Agency to launch a clinical study in Britain with its new painkiller, PTI-801. ...

Ariba to deliver sourcing solution to AstraZeneca.(contract details)(Brief Article)
January 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish pharmaceutical company AstraZeneca Plc has selected California-based Ariba Inc to provide it with a system that will streamline procurement processes at its business...

A-VIRAL uses new technology to show efficacy of AIDS treatment.(research techniques review)(Brief Article)
January 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Norwegian biotechnology company A-VIRAL reports that it has developed a technology that can measure the quality of white blood cells in patients that are treated with AIDS drugs. ...

BioPhausia awarded Europe-wide patent for cancer treatment.(pharmaceutical patent details)
January 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish pharmaceutical company BioPhausia AB reports that it has received a patent in 17 European countries for its BP04 cancer treatment method. The patent covers the way BP04...

AstraZeneca faces lawsuit in USA.(class action lawsuit details)(Brief Article)
January 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A so-called class-action lawsuit has been filed in the United States against the Anglo-Swedish pharmaceutical company AstraZeneca Plc. The lawsuit was filed in a Florida district...

Q-Med begins distribution agreement negotiations.(contract details)(Brief Article)
January 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology and medical devices company Q-Med AB has signed an agreement with an unnamed company regarding the distribution of DUROLANE, its drug for the treatment of...

Doxa Certex gets US approval for tooth filling material.(DoxaDent)(Brief Article)
January 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US Food and Drug Administration has given the Swedish dental products supplier Doxa Certex AB permission to market its DoxaDent tooth filling material in US markets. DoxaDent,...

Elan and Wyeth-Ayerst suspend dosing in trial for Alzheimer's disease treatment.(Elan Corp Plc, Wyeth-Ayerst Laboratories)(Brief Article)
January 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Irish pharmaceutical company Elan Corp Plc and its partner Wyeth-Ayerst Laboratories have suspended dosing in the five-country phase IIa clinical study of AN-1792, their experimental...

Tripep unveils plan to free resources for acquisitions.(company management strategy review)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Tripep AB has adopted a new business plan to free resources for the acquisition of research firms and the inlicensing of projects currently in the...

GlaxoSmithKline encourages HIV testing through new web site.(for gay community)(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK pharmaceutical group GlaxoSmithKline has teamed with the Victoria Clinic for Sexual Health to launch a web site that aims to encourage HIV testing in the gay community. The...

>TI Roche has production problem with liquid Tamiflu.(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swiss drugs and diagnostics group Roche Holding AG has confirmed that there is a production problem with the liquid version of its Tamiflu influenza treatment. Roche's spokesman...

>TI Karo Bio expects rapid consolidation among Nordic biotech companies.(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Karo Bio AB is ready to make new acquisitions but is not actively looking for targets. The chief executive of Karo Bio, Bjorn Nilsson, says...

>TI Pharmacia and deCODE team to hunt for heart disease genes.(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US-Swedish pharmaceutical group Pharmacia Corp and the Icelandic biotechnology company deCODE Genetics have partnered to jointly identify the role of genetics in the development of...

>TI GlaxoSmithKline's COPD treatments recommended for FDA approval.(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD An advisory committee of the US Food and Drug Administration (FDA) has recommended that the authority should approve two dose strengths of GlaxoSmithKline Plc's Advair Diskus and Flovent...

AstraZeneca told to remove advertisements.(Brief Article)
January 21, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US Food and Drug Administration (FDA) says that the Anglo-Swedish drug group AstraZeneca Plc has used misleading advertising for its Nolvadex breast cancer drug. In its letter...

>TI Prevas Bioinformatics to develop data management system for Biovitrum.(Brief Article)
January 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish IT consultancy Prevas Bioinformatics has won a contract to develop a data management system for the research organisation of the Stockholm-based biotechnology company Biovitrum...

>TI Japan approves long-acting version of AstraZeneca's prostate cancer drug.
January 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish pharmaceutical group AstraZeneca Plc has received approval from the Japanese health authorities to market its Zoladex Long Acting product as a treatment for prostate...

>TI AstraZeneca's drug licence application gets 'fast track' status in USA.(Brief Article)
January 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca reports that the US Food and Drug Administration (FDA) has granted so-called 'fast track' status for the company's supplementary licence...

>TI Roche Diagnostics ordered to pay damages to IGEN International.(Brief Article)
January 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A US district court has ordered Roche Diagnostics, a unit of the Swiss drugs and diagnostics group Roche Holding AG, to pay USD505m in damages to the US-based biotechnology company IGEN...

>TI Sanofi-Synthelabo transfers rights to epilepsy drug to Cephalon.(Brief Article)
January 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The French pharmaceutical group Sanofi-Synthelabo has agreed to transfer its licensing and property rights for Gabitril, a drug that helps prevent the occurrence of epileptic seizures, to...

IDL Biotech signs collaboration agreement with Lund University.(agreement details)(Brief Article)
January 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company IDL Biotech AB has teamed up with a research team at Lund University in southern Sweden to develop tests for the detection of infections caused by the...

PhotoCure submits application for cancer therapy in Switzerland.(Metvix photodynamic therapy )(Brief Article)
January 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Norwegian biotechnology company PhotoCure ASA has submitted a marketing authorisation application to the Swiss regulatory authorities for its Metvix photodynamic therapy (PDT). ...

Qiagen opens North American headquarters.(Qiagen NV's subsidiary, Qiagen Sciences Inc)(Brief Article)
January 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Dutch biotechnology company Qiagen NV has opened the new headquarters of its wholly owned US subsidiary, Qiagen Sciences Inc. The 200,000 square foot facility, which includes a...

>TI Flamel and Novo Nordisk terminate insulin development partnership.(Flamel Technologies S.A., Basulin)(Brief Article)
January 14, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The French biotechnology company Flamel Technologies SA and the Danish pharmaceutical firm Novo Nordisk A/S have ended their licence agreement regarding the Basulin insulin product. ...

>TI DSM licenses animal feed enzymes to Novozymes.(Brief Article)
January 14, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Novozymes A/S and the Dutch chemicals and materials group DSM have signed a licensing agreement. Under the agreement DSM grants a worldwide,...

>TI Novo Nordisk affiliate files for initial public offering.
January 14, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD ZymoGenetics Inc, in which the Danish biotechnology firm Novo Nordisk is the largest shareholder with a 47% stake, has filed an amendment to the registration statement it filed in...

>TI Elekta wins radiotherapy equipment orders worth SEK120m.(Brief Article)
January 14, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish medical technology company Elekta AB has won contracts to deliver radiotherapy equipment to a number of North American cancer clinics. Elekta devices offer intensity...

Novo Nordisk and DGI BioTechnologies team to discover anticancer agents.(Brief Article)
January 11, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish pharmaceutical company Novo Nordisk A/S and the US-based biotechnology firm DGI BioTechnologies Inc have signed a two-year licensing and research agreement. Under the...

Acadia Pharmaceuticals and Amgen form drug discovery partnership.(Brief Article)
January 11, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish-US drug discovery/development company Acadia Pharmaceuticals has signed a collaboration agreement with the US biotechnology company Amgen Inc. As part of the agreement...

>TI deCODE to acquire MediChem Life Sciences.(Brief Article)
January 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Icelandic biotech company deCODE genetics has signed a definitive agreement to acquire US-based MediChem Life Sciences Inc in a stock-for-stock exchange worth approximately USD83.6m....

>TI Britain's Special Airforce Services to use BioPhausia's product.(Brief Article)
January 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish pharmaceutical company BioPhausia has received an order for RescueFlow, its volume substitution solution for trauma situations, from the British Special Airforce Services...

>TI Oxford Glycosciences, Medarex and Genmab form partnership.(Brief Article)
January 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Britain's Oxford Glycosciences Plc, US-based Medarex Inc and Denmark's Genmab A/S have formed a partnership to jointly develop new medical products for the treatment of breast cancer. ...

>TI Igene Biotechnology acquires ProBio Nutraceuticals.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US-based biochemical products manufacturer Igene Biotechnology Inc has signed an agreement to purchase ProBio Nutraceuticals for USD2.2m in cash, stock and convertible promissory...

>TI Gyros and ACE Biosciences team to test new sample preparation technology.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish laboratory process technology developer Gyros AB and the Danish biotechnology company ACE BioSciences A/S have signed a collaboration agreement. Under the agreement a...

>TI Recordati to sell Lundbeck's new antidepressant in Italy.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish drugmaker H. Lundbeck A/S has signed a co-marketing agreement with the Italian-based pharmaceutical group Recordati. The two companies have co-marketed Lundbeck's...

>TI Antisoma unveils plan to raise up to GBP20m in funding.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK biotechnology company Antisoma Plc says that it will take over the funding of its lead drug, after its US-based marketing partner Abbott Laboratories Inc refused to finance more...

>TI US health authorities approve MediTeam's dental instrument.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish dental care products maker MediTeam has received approval from the US Food and Drug Administration (FDA) to market its PowerDrive instrument in US markets. The FDA has...

>TI Merck & Co to utilise Delta Biotechnology's protein in new vaccine.
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Delta Biotechnology, part of the French-German drugs and chemical group Aventis SA, will provide its Recombumin protein ingredient to Merck & Co for use in the US pharmaceutical...

GlaxoSmithKline to introduce drugs quota system in Europe.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK pharmaceutical company GlaxoSmithKline Plc (GSK) has notified the European Union that it wants to restrict drug sales to wholesalers in order to prevent the resale of surplus...

>TI Schering acquires full ownership of French radiopharmaceutical firm.(Brief Article)
January 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German pharmaceutical company Schering AG has acquired the 40% stake in the French firm CIS bio international SA it did not already own. Schering, which bought the stake from the...

MAP Medical Technologies licenses European rights for diagnostic test product.(Brief Article)
January 7, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD US-based Guilford Pharmaceuticals Inc has signed a licensing agreement with the Finnish company MAP Medical Technologies. Under the agreement MAP and its affiliated companies receive...

Public prosecutor closes investigation of Baxter's Swedish plant.(Brief Article)
January 7, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A Swedish prosecutor has dropped his criminal inquiry of US-based Baxter International Inc's plant in Ronneby, Sweden. The prosecutor, Tommy Clevenhult, launched the investigation in...

AstraZeneca submits clinical data for cancer drug to US authorities.(Brief Article)
January 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has submitted a clinical data package to the US Food and Drug Administration to support its marketing application for the new cancer drug...

Provita introduces spray for foot infections in animals.(Brief Article)(Product Announcement)
January 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK pharmaceutical company Provita Eurotech Ltd has launched a new film-forming spray for the control of foot infections in cattle and sheep. The Combat product, which contains tea...

H. Lundbeck's depression drug approved in Switzerland.(Brief Article)(Product Announcement)
January 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish pharmaceutical company H. Lundbeck A/S' Cipralex drug has been approved by the Swiss health authorities as a treatment for depression. Lundbeck now expects to introduce...

EU health authorities approve AstraZeneca's asthma drug for children.(Brief Article)
January 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD AstraZeneca Plc's Oxis Turbuhaler product has been approved by all the European Union countries expect France for maintenance treatment of asthma in children aged six years and over. ...

Shire and HydroMed team to develop prostate cancer treatment.(Shire Pharmaceuticals PLC, HydroMed Sciences Inc.)(Brief Article)
January 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Shire Pharmaceuticals Plc has signed a licensing and development agreement with the US company HydroMed Sciences Inc. Under the agreement the companies will work together to...